產(chǎn)品目錄

規(guī)格	1 mg
CAS	2070009-25-3
別名	N/A
化學名	N/A
分子式	C21[13C]H26D3FN3O9P
分子量	533.5
溶解度	DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 0.2 mg/ml
儲存條件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

PSI-7977-13C-d3 is intended for use as an internal standard for the quantification of PSI-7977 by GC- or LC-MS. PSI-7977 is a phosphoramidate prodrug of PSI-7851, a nucleoside analog that, when phosphorylated, inhibits the RNA-dependent RNA polymerase of hepatitis C virus (EC50 = 92 nM).1,2,3 PSI-7977 is effective in vitro and in vivo.2,4,5

1.Murakami, E., Tolstykh, T., Bao, H., et al.Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977J. Biol. Chem.285(45)34337-34347(2010) 2.Sofia, M.J., Bao, D., Chang, W., et al.Discovery of a β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virusJ. Med. Chem.53(19)7202-7218(2010) 3.Lam, A.M., Espiritu, C., Bansal, S., et al.Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virusAntimicrob. Agents Chemother.56(6)3359-3368(2012) 4.Gane, E.J., Stedman, C.A., Hyland, R.H., et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis CN. Engl. J. Med.368(1)34-44(2013) 5.Lawitz, E., Mangia, A., Wyles, D., et al.Sofosbuvir for previously untreated chronic hepatitis C infectionN. Engl. J. Med.368(20)1878-1887(2013)

特別提醒：

1. 本產(chǎn)品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請穿好實驗服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項：

1.遵守中華人民共和國有關法律、法規(guī)，尊重網(wǎng)上道德，承擔一切因您的行為而直接或間接引起的法律責任。

2.請您真實的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個人或團體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細地址*
常用郵箱*
請輸入您對我們的意見或建議*
驗證碼*